| CPC A61B 1/0638 (2013.01) [A61B 1/00188 (2013.01); A61B 1/043 (2013.01); A61B 1/05 (2013.01); A61B 1/0684 (2013.01); A61B 5/0071 (2013.01)] | 11 Claims |
|
1. A method for identifying a formation process of a malignant tumor, wherein the method comprises:
Step 1: providing an optical observation equipment for identifying the forming process of the malignant tumor, wherein the optical observation equipment has a receiving space and a transparent front end, and the optical observation equipment comprises:
a light-guide fiber, an input end of which extends to the receiving space and an output end of which extends to the transparent front end;
a laser emitter, which is disposed in the receiving space and emits laser light with a wavelength of 340 nm±20 nm and an energy in a range from 0.3mj/m2 to 0.5mj/m2 in a pulsing mode;
a focusing device comprising a focusing mirror, which is disposed in the receiving space and coupled to an output end of the laser emitter, and which is used for focusing the laser light to the input end of the light-guide fiber;
a white light emitter, which is disposed in the receiving space and emits white light, and the white light is guided into the input end of the light-guide fiber;
an image sensor, which is disposed in the transparent front end, and which is configured to be used for acquiring an image of an area irradiated by the white or the laser light emitted from the output end of the light-guide fiber and converting a light signal into an electric signal; and
a gain amplifier, which is coupled to the image sensor and is used for amplifying the electric signal generated by the image sensor;
Step 2: aligning the transparent front end of the optical observation equipment with a tissue to be detected;
Step 3: irradiating the tissue to be detected with a white light emitted from the output end of the light-guide fiber;
Step 4: displaying an image of the tissue to be detected which is irradiated by the white light in a display, and identifying a suspected tissue area;
Step 5: irradiating the suspected tissue area with the laser light emitted from the output end of the light-guide fiber in a pulse mode;
Step 6: displaying a fluorescence image of the suspected tissue area which is irradiated by the laser light in the display, and obtaining a fluorescence spectrum of the tissue,
wherein the fluorescence spectrum generated is all in the visible light band of 400 nm-700 nm;
Step 7: identifying whether or not the suspected tissue area is relevant to the malignant tumor formation on the basis of the fluorescence spectrum, wherein a peak value at 460 nm=20 nm of a fluorescence spectrum of a normal tissue is used as a reference value, and wherein the identifying whether or not the suspected tissue area is relevant to the malignant tumor formation on the basis of the fluorescence spectrum comprises:
determining whether the fluorescence spectrum of the tissue has a peak value at 460 nm±20 nm that is 100% of the reference value, and the fluorescence spectrum of the tissue has no peak values at 400-20 nm and 670+20 nm, thereby identifying whether the tissue is the normal tissue;
determining whether the fluorescence spectrum of the tissue has a peak value at 460 nm±20 nm that is more than 60% of the reference value, and the fluorescence spectrum of the tissue has no peak values at 400-20 nm and 670±20 nm of the fluorescence spectrum, thereby identifying whether the tissue is a benign lesion tissue;
determining whether the fluorescence spectrum of the tissue has a peak value at 460 nm±20 nm that is less than 40% of the reference value, and the fluorescence spectrum of the tissue has peak values at 400 nm±20 nm and 670 nm±20 nm, thereby identifying whether the tissue is the malignant tumor tissue;
determining whether the fluorescence spectrum of the tissue has a peak value at 460 nm±20 nm that is less than 40% of the reference value, the fluorescence spectrum of the tissue has a peak value at 400 nm±20 nm, and the fluorescence spectrum of the tissue has no peak value at 670 nm±20 nm, thereby identifying whether the tissue is identified as a severe atypical hyperplasia tissue;
determining whether the fluorescence spectrum of the tissue has a peak value at 460 nm±20 nm that is less than 40% of the reference value, the fluorescence spectrum of the tissue has a peak value at 670 nm±20 nm, and the fluorescence spectrum of the tissue has no peak value at 400 nm±20 nm, thereby identifying whether the tissue is identified as a severe atypical hyperplasia tissue; and
determining whether the fluorescence spectrum of the tissue has a peak value at 460 nm±20 nm that is less than 40% of the reference value, and the fluorescence spectrum of the tissue has no peak values at 400 nm±20 nm and 670 nm±20 nm, thereby identifying whether the tissue is identified as a mild or moderate atypical hyperplasia tissue;
Step 8: mapping a curve profile of the fluorescence spectrum of the tissue as a fluorescence chromatographic energy diagram, wherein the fluorescence chromatographic energy diagram is a color image in which different wavelengths of the fluorescence spectrum are mapped to specific colors including at least one of red, orange, yellow, green, blue, indigo, purple, and wherein a whole spectrum band of 400 nm-700 nm is distributed in the visible light band, an intensity of a peak represents an intensity of a color, and peak values of different wavelengths exhibit different colors, so that doctors can directly identify a nature of a lesion according to fluorescent color of the lesion through visual method.
|